KeyBanc analyst Brett Fishbin raised the firm’s price target on Axonics to $71 from $70 and keeps an Overweight rating on the shares. The trajectory of SNM and Bulkamid is encouraging and KeyBanc believes Q2 demonstrated its ability to drive significant operating leverage over time, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX: